PURE Bioscience (OTCQB: PURE) grows Q2 2026 sales while narrowing year-over-year loss

Rhea-AI Filing Summary

PURE Bioscience, Inc. reported fiscal second quarter 2026 results, showing modest growth with continued losses. Net product sales for the quarter rose to $443,000 from $391,000 a year earlier, while net loss was roughly flat at $785,000 versus $798,000.

For the six months ended January 31, 2026, net product sales increased to $1,150,000 from $946,000, and net loss improved to $1,249,000 from $1,487,000, helped by lower selling, general and administrative costs. Net loss per share remained at $(0.01) for both periods.

The balance sheet shows limited liquidity, with cash and cash equivalents of $198,000 and restricted cash of $75,000 at January 31, 2026, against total liabilities of $7,061,000 and a stockholders’ deficiency of $6,273,000. Common shares issued and outstanding were 111,886,473.

Operationally, PURE obtained USDA Biobased Product Certification for its new product PURE Clean and expects to launch it and fulfill pre-orders in the fiscal third quarter. The company is expanding applications in dairy plants, transportation, and exploring biomedical opportunities through partners, aiming to grow recurring revenue from its SDC-based antimicrobial technology.

false 0001006028 0001006028 2026-03-16 2026-03-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 16, 2026

PURE BIOSCIENCE, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-14468		33-0530289
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

771 Jamacha Rd., #512 El Cajon, California		92019
(Address of principal executive offices)		(Zip Code)

9669 Hermosa Avenue Rancho Cucamonga, California		91730
(Address of principal executive offices)		(Zip Code)

(Former name or former address, if changed since last report)

Registrant’s telephone number, including area code: (619) 596-8600

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act: None

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On March 16, 2026, PURE Bioscience, Inc. (the “Company”) issued a press release announcing financial results for the fiscal second quarter ended January 31, 2026 and related information. A copy of the press release is attached as Exhibit 99.1.

The information in this Item 2.02 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that Section. The information in this Item 2.02 shall not be incorporated by reference into any registration statement or other document filed with the Securities and Exchange Commission.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

	99.1	Press Release, dated March 16, 2026.
	104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

* Exhibit 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that Section, nor shall it be incorporated by reference into any registration statement or other document filed with the Securities and Exchange Commission.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	PURE BIOSCIENCE, INC.
Dated: March 16, 2026	By:	/s/ Robert F. Bartlett
		Robert F. Bartlett
		Chief Executive Officer

EXHIBIT INDEX

Exhibit Number		Description
99.1		Press Release, dated March 16, 2026.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

Exhibit 99.1

PURE Bioscience Reports Fiscal Second Quarter 2026

Financial Results

EL CAJON, Calif. – PURE Bioscience, Inc. (OTCQB: PURE) (“PURE,” the “Company” or “we”), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, today reported financial results for the fiscal second quarter ended January 31, 2026.

Summary of Results – Fiscal Second Quarter Operations

	●	Net product sales were $443,000 and $391,000 for the fiscal second quarters ended January 31, 2026 and 2025, respectively. The increase of $52,000 was attributable to increased sales across our end-user network.
	●	Net loss for the fiscal second quarter ended January 31, 2026 was $785,000, compared to $798,000 for the fiscal second quarter ended January 31, 2025. During the current quarter, selling, general and administrative expenses decreased by $24,000 due to reductions in board fees and personnel costs. These reductions were offset by increased interest expense related to the Company’s notes payable balance.
	●	Net loss, excluding share-based compensation, for the fiscal second quarter ended January 31, 2026, was $727,000, compared to $771,000 for the fiscal second quarter ended January 31, 2025.
	●	Net loss per share was ($0.01) for the fiscal second quarters ended January 31, 2026 and 2025, respectively.

Summary of Results – Prior Six Months

	●	Net product sales were $1,150,000 and $946,000 for the six months ended January 31, 2026 and 2025, respectively. The increase of $204,000 was attributable to increased sales across our end-user network.
	●	Net loss for the six months ended January 31, 2026 was $1,249,000, compared to $1,487,000 for the six months ended January 31, 2025. Selling, general and administrative expenses decreased by $162,000 due to reductions in board fees and personnel costs. These reductions were offset by increased interest expense related to the Company’s notes payable balance.
	●	Net loss, excluding share-based compensation, for the six months ended January 31, 2026, was $1,157,000, compared to $1,403,000 for the six months ended January 31, 2025.
	●	Net loss per share was ($0.01) for the six months ended January 31, 2026 and 2025, respectively.

Business Update

	●	We received the long-awaited USDA Biobased Product Certification on our new product, PURE Clean.
	●	We expect to officially launch PURE Clean and fulfill pre-orders in the fiscal third quarter.
	●	PURE continues to validate and roll out our new in-plant dairy applications through testing and trial at Cal Poly San Luis Obispo.
	●	We began a new marketing campaign directly targeting dairy farmers, which highlights our new membrane and pasteurizer treatments.
	●	We started exploring new opportunities with our key partner, Quip Laboratories, in the biomedical space, a new vertical market.
	●	Our distribution partner, Bonsai, is leveraging its online platform to expand promotion and sales of PURE products with the business-to-business janitorial and sanitation market, while strategically broadening consumer access.
	●	PURE has seen continued growth in the sale of products and equipment in the transportation industry, facilitated by the development of new equipment specifically designed for trailer treatments.

Tim Steffensmeier, Vice President of Sales, stated, “The Company is advancing with disciplined execution. We are converting in-plant validations into recurring commercial programs, deepening our presence within the food and beverage vertical, and preparing to launch PURE Clean following its USDA BioPreferred® Program certification. At the same time, we are strategically expanding into the food transportation sector and the biomedical space through focused partnerships, while positioning PURE solutions for broader market accessibility through complementary channels. Our priority is clear - accelerate adoption, diversify with intention, and expand market reach to drive sustained revenue growth.”

About PURE Bioscience, Inc.

PURE is committed to redefining chemical safety through its innovative technology. With a focus on efficacy and effectiveness, PURE develops advanced solutions that meet the highest safety standards and produce best-in-class results for its consumers and distributors. PURE continues to focus on developing and commercializing our proprietary antimicrobial products, primarily in the food and beverage industry. We provide solutions to combat the health and environmental challenges posed by pathogens and ensure hygienic control. Our technology platform is based on patented, stabilized ionic silver, and our products contain silver dihydrogen citrate, better known as SDC. This broad-spectrum, non-toxic antimicrobial agent formulates well with other compounds. As a platform technology, SDC is distinguished from existing products in the marketplace because of its superior efficacy, reduced toxicity, and mitigation of bacterial resistance. Additional information on PURE is available at www.purebio.com.

Forward-looking Statements: Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Statements in this press release, including quotes from management, concerning the Company’s expectations, plans, business outlook, future performance, future potential revenues, expected results of the Company’s marketing efforts, the execution of contracts under negotiation, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are “forward-looking statements.” Forward-looking statements inherently involve risks and uncertainties that could cause our actual results to differ materially from any forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, the Company’s failure to implement or otherwise achieve the benefits of its proposed business initiatives and plans; acceptance of the Company’s current and future products and services in the marketplace, including the Company’s ability to convert successful evaluations and tests for PURE products into customer orders and customers continuing to place product orders as expected and to expand their use of the Company’s products; the Company’s ability to maintain relationships with its partners and other counterparties; the Company’s ability to generate sufficient revenues and reduce its operating expenses in order to reach profitability; the Company’s ability to raise the funding required to support its continued operations and the implementation of its business plan; the ability of the Company to develop effective new products and receive required regulatory approvals for such products, including the required data and regulatory approvals required to use its SDC-based technology; competitive factors, including customer acceptance of the Company’s SDC-based products that are typically more expensive than existing treatment chemicals; dependence upon third-party vendors, including to manufacture its products; and other risks detailed in the Company’s periodic report filings with the Securities and Exchange Commission (the SEC), including its Form 10-K for the fiscal year ended July 31, 2025, Form 10-Q for the fiscal first quarter ended October 31, 2025, and Form 10-Q for the fiscal second quarter ended January 31, 2026. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.

Contact:

Mark Elliott, VP Finance

PURE Bioscience, Inc.

619-596-8600

PURE Bioscience, Inc.

Condensed Consolidated Balance Sheets

		January 31, 2026				July 31, 2025
			(Unaudited)
Assets
Current assets
Cash and cash equivalents		$	198,000			$	334,000
Accounts receivable			252,000				474,000
Inventories, net			244,000				141,000
Restricted cash			75,000				75,000
Prepaid expenses			10,000				23,000
Total current assets			779,000				1,047,000
Property, plant and equipment, net			9,000				11,000
Total assets		$	788,000			$	1,058,000
Liabilities and stockholders’ deficiency
Current liabilities
Accounts payable		$	767,000			$	784,000
Convertible notes payable to related parties, current			2,139,000				—
Accrued liabilities			149,000				154,000
Total current liabilities			3,055,000				938,000
Convertible notes payable to related parties, non-current			4,006,000				5,236,000
Total liabilities			7,061,000				6,174,000
Commitments and contingencies
Stockholders’ deficiency
Preferred stock, $0.01 par value: 5,000,000 shares authorized, no shares issued and outstanding			—				—
Common stock, $0.01 par value: 200,000,000 shares authorized, 111,886,473 shares issued and outstanding at January 31, 2026, and July 31, 2025			1,119,000				1,119,000
Additional paid-in capital			132,851,000				132,759,000
Accumulated deficit			(140,243,000	)			(138,994,000	)
Total stockholders’ deficiency			(6,273,000	)			(5,116,000	)
Total liabilities and stockholders’ deficiency		$	788,000			$	1,058,000

PURE Bioscience, Inc.

Condensed Consolidated Statements of Operations

(Unaudited)

		Six Months Ended								Three months Ended
		January 31,								January 31,
		2026				2025				2026				2025
Net product sales		$	1,150,000			$	946,000			$	443,000			$	391,000
Royalty revenue			2,000				1,000				1,000				—
Total revenue			1,152,000				947,000				444,000				391,000
Cost of goods sold			464,000				395,000				206,000				164,000
Gross profit			688,000				552,000				238,000				227,000
Operating costs and expenses
Selling, general and administrative			1,590,000				1,752,000				847,000				871,000
Research and development			160,000				152,000				74,000				81,000
Total operating costs and expenses			1,750,000				1,904,000				921,000				952,000
Loss from operations			(1,062,000	)			(1,352,000	)			(683,000	)			(725,000	)
Other income (expense)
Other income (expense), net			8,000				(3,000	)			(1,000	)			(3,000	)
Interest expense, net			(195,000	)			(132,000	)			(101,000	)			(70,000	)
Total other income (expense)			(187,000	)			(135,000	)			(102,000	)			(73,000	)
Net loss		$	(1,249,000	)		$	(1,487,000	)		$	(785,000	)		$	(798,000	)
Basic and diluted net loss per share		$	(0.01	)		$	(0.01	)		$	(0.01	)		$	(0.01	)
Shares used in computing basic and diluted net loss per share			111,886,473				111,856,473				111,886,473				111,856,473

FAQ

How did PURE (PURE) perform in its fiscal Q2 2026?

PURE Bioscience posted modest revenue growth with continued losses. Net product sales rose to $443,000 from $391,000, while net loss was $785,000 compared with $798,000 a year earlier, and net loss per share stayed at $(0.01).

What were PURE (PURE) results for the six months ended January 31, 2026?

Six-month revenue increased and losses narrowed year over year. Net product sales were $1,150,000 versus $946,000, and net loss improved to $1,249,000 from $1,487,000, with net loss per share unchanged at $(0.01).

What is PURE Bioscience’s (PURE) cash and debt position as of January 31, 2026?

PURE reported low cash against sizable liabilities. Cash and cash equivalents were $198,000 and restricted cash $75,000, while total liabilities were $7,061,000, contributing to a stockholders’ deficiency of $6,273,000 at January 31, 2026.

What new product developments did PURE (PURE) highlight in this report?

PURE obtained USDA Biobased Product Certification for PURE Clean. The company plans to officially launch PURE Clean and fulfill pre-orders in the fiscal third quarter, positioning it as a new biobased cleaning solution within its antimicrobial product portfolio.

Which markets is PURE Bioscience (PURE) targeting for growth?

PURE is focusing on food, beverage, transportation, and biomedical sectors. It is validating in-plant dairy applications, marketing membrane and pasteurizer treatments to dairy farmers, expanding transportation equipment treatments, and exploring biomedical opportunities with partners like Quip Laboratories and Bonsai.

How are PURE (PURE) operating expenses and losses trending?

Operating expenses decreased, helping reduce net losses. For the six months ended January 31, 2026, selling, general and administrative expenses fell to $1,590,000 from $1,752,000, contributing to a net loss improvement from $1,487,000 to $1,249,000.

Filing Exhibits & Attachments

4 documents

Press Releases

• EX-99.1 EX-99.1 59.1 KB

Other Documents

• EX-101 XBRL SCHEMA FILE 2.9 KB
• EX-101 XBRL LABEL FILE 33.4 KB
• EX-101 XBRL PRESENTATION FILE 21.8 KB